12:00 AM
Dec 03, 2012
 |  BC Week In Review  |  Company News  |  Other News

Amarin cardiovascular news

Amarin said the U.S. Patent and Trademark Office (PTO) issued a notice of allowance for Patent Application No. 13/610,247. The patent covers claims for Vascepa icosapent ethyl (formerly AMR101) to treat hypertriglyceridemia -- its approved indication. The application claims cover the use of Vascepa with and without other lipid lowering agents such as statins. According to the company, a similar application -- Patent Application No. 13/608,775 -- received a notice of allowance from the...

Read the full 366 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >